Anticoagulants are the cornerstone for prevention and treatment of thrombosis but are not
completely effective, and concerns about the risk of bleeding continue to limit their uptake …

Coagulation factor XII (FXII), a S1A serine protease, was discovered more than fifty years
ago. However, its in vivo functions and its three-dimensional structure started to be disclosed …

Thrombo-inflammation describes the complex interplay between blood coagulation and
inflammation that plays a critical role in cardiovascular diseases. The third Maastricht …

Platelets are the main players in thrombotic diseases, where activated platelets not only
mediate thrombus formation but also are involved in multiple interactions with vascular cells …

Extracellular protein disulfide isomerase (PDI) is a promising target for thrombotic-related
diseases. Four potent PDI inhibitors with unprecedented chemical architectures, piericones …

Micro/nanomotors (MNMs) can significantly enhance bioadhesion and tissue penetration
due to their ability of autonomous motion compared with traditional passive cargo delivery …

Remarkable progress has been made in the pharmacological management of patients with
cardiovascular disease, including the frequent use of antithrombotic agents. Nonetheless …

The continuous upsurge in drug resistance, the proliferation of life‐threatening aliment, and
the advent of the utilization of biogenic extract for bio‐fabrication of metallic nanoparticles …

Parenteral and oral factor XI (FXI) inhibitors, the next potential generation of anticoagulants,
are undergoing phase-3 evaluation with the hope that they will be safer than currently …

From the 1940s to 1990s, heparin and warfarin have been the main anticoagulants for the
prevention and treatment of thrombotic events. Since then, LMWHs and fondaparinux …